264 related articles for article (PubMed ID: 27401557)
61. HGF/MET signaling in ovarian cancer.
Zhou HY; Pon YL; Wong AS
Curr Mol Med; 2008 Sep; 8(6):469-80. PubMed ID: 18781954
[TBL] [Abstract][Full Text] [Related]
62. FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.
Stanicka J; Rieger L; O'Shea S; Cox O; Coleman M; O'Flanagan C; Addario B; McCabe N; Kennedy R; O'Connor R
Oncogene; 2018 Jun; 37(23):3131-3150. PubMed ID: 29540831
[TBL] [Abstract][Full Text] [Related]
63. Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.
Fan G; Lin G; Lucito R; Tonks NK
J Biol Chem; 2013 Aug; 288(34):24923-34. PubMed ID: 23814047
[TBL] [Abstract][Full Text] [Related]
64. MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
Chen D; Cao L; Wang X
Oncol Rep; 2019 Aug; 42(2):679-687. PubMed ID: 31233194
[TBL] [Abstract][Full Text] [Related]
65. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
Moran-Jones K
Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
[TBL] [Abstract][Full Text] [Related]
66. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.
Zhang Y; Xiong X; Sun R; Zhu X; Wang C; Jiang B; Yang X; Li D; Fan G
J Biol Chem; 2023 Jun; 299(6):104825. PubMed ID: 37196766
[TBL] [Abstract][Full Text] [Related]
67. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.
Maggiora P; Lorenzato A; Fracchioli S; Costa B; Castagnaro M; Arisio R; Katsaros D; Massobrio M; Comoglio PM; Flavia Di Renzo M
Exp Cell Res; 2003 Aug; 288(2):382-9. PubMed ID: 12915129
[TBL] [Abstract][Full Text] [Related]
68. Role of feline sarcoma‑related protein in the viability and apoptosis of bladder cancer cells.
Hu X; Guo Z; Xu J; Mei X; Bi M; Jiang F; Yu D; Zhong C
Mol Med Rep; 2019 Jun; 19(6):5219-5226. PubMed ID: 31059042
[TBL] [Abstract][Full Text] [Related]
69. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.
Demkova L; Kucerova L
Mol Cancer; 2018 Feb; 17(1):26. PubMed ID: 29455657
[TBL] [Abstract][Full Text] [Related]
70. SKOR1 mediates FER kinase-dependent invasive growth of breast cancer cells.
Sluimer LM; Bullock E; Rätze MAK; Enserink L; Overbeeke C; Hornsveld M; Brunton VG; Derksen PWB; Tavares S
J Cell Sci; 2023 Feb; 136(3):. PubMed ID: 36620935
[TBL] [Abstract][Full Text] [Related]
71. Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER.
Kim L; Wong TW
J Biol Chem; 1998 Sep; 273(36):23542-8. PubMed ID: 9722593
[TBL] [Abstract][Full Text] [Related]
72. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.
Hwang CI; Choi J; Zhou Z; Flesken-Nikitin A; Tarakhovsky A; Nikitin AY
Cell Cycle; 2011 Nov; 10(22):3834-40. PubMed ID: 22071625
[TBL] [Abstract][Full Text] [Related]
73. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Pennacchietti S; Michieli P; Galluzzo M; Mazzone M; Giordano S; Comoglio PM
Cancer Cell; 2003 Apr; 3(4):347-61. PubMed ID: 12726861
[TBL] [Abstract][Full Text] [Related]
74. Met and the microenvironment: new insights for ovarian cancer metastasis.
Sourbier C
Cell Adh Migr; 2011; 5(3):209-10. PubMed ID: 21436615
[TBL] [Abstract][Full Text] [Related]
75. Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.
Felici A; Giubellino A; Bottaro DP
J Cell Biochem; 2010 Oct; 111(2):310-21. PubMed ID: 20506405
[TBL] [Abstract][Full Text] [Related]
76. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.
Locatelli A; Lofgren KA; Daniel AR; Castro NE; Lange CA
Horm Cancer; 2012 Apr; 3(1-2):14-25. PubMed ID: 22124844
[TBL] [Abstract][Full Text] [Related]
77. Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion.
Vadnais J; Nault G; Daher Z; Amraei M; Dodier Y; Nabi IR; Noël J
J Biol Chem; 2002 Dec; 277(50):48342-50. PubMed ID: 12372820
[TBL] [Abstract][Full Text] [Related]
78. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
[TBL] [Abstract][Full Text] [Related]
79. Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering.
Li W; Dick A; Lu F; Zhang H; Sun H
Sci Rep; 2019 Feb; 9(1):1988. PubMed ID: 30760737
[TBL] [Abstract][Full Text] [Related]
80. Met, metastasis, motility and more.
Birchmeier C; Birchmeier W; Gherardi E; Vande Woude GF
Nat Rev Mol Cell Biol; 2003 Dec; 4(12):915-25. PubMed ID: 14685170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
